Increasing Hypersensitivity Pneumonitis–related Mortality in the United States from 1988 to 2016

Contemporary Concise Review 2018: Interstitial lung disease

“…HP, formerly ‘extrinsic allergic alveolitis’, is an immunologically mediated ILD that resulted from inhalation exposure of a great variety of antigens. The analysis of the overall survival in HP from 1988 to 2016 was the focus of a retrospective work that describes an age‐adjusted HP‐related mortality rate increase from 0.12 to 0.68 per 1.000.000 subjects in the year 2016. Thus, the burden of HP is far from being fully defined, and many questions about progression and treatment need to be addressed.…”

Hypersensitivity Pneumonitis Mortality by Industry and Occupation

“…We read with interest the research letter by Fernández Pérez and colleagues (1) and agree that population-level mortality from hypersensitivity pneumonitis (HP) has not been well characterized in the United States. However, the role of occupation in the development and severity of HP is well established (2–4).…”

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis

“…Between 56% and 68% of HP cases per year are considered chronic disease (prevalence 0.9–1.7 per 100 000 persons) and among chronic cases approximately 36–48% have pulmonary fibrosis [ 1 ]. A large proportion of patients with fibrotic HP develop symptomatic, functional and radiographic disease progression [ 2 – 4 ]. Progressive fibrotic HP (FHP) has a mortality rate comparable to idiopathic pulmonary fibrosis (IPF), with an estimated mean survival of 3–5 years from the time of diagnosis [ 2 , 5 , 6 ].…”